Vanda Pharmaceuticals’ (VNDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Tuesday,Benzinga reports. They currently have a $18.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Monday. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Up 1.6 %

Shares of VNDA stock opened at $4.42 on Tuesday. The firm’s fifty day moving average price is $4.77 and its two-hundred day moving average price is $5.02. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The firm has a market capitalization of $257.73 million, a P/E ratio of -15.79 and a beta of 0.77.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VNDA. SG Americas Securities LLC lifted its holdings in Vanda Pharmaceuticals by 26.8% during the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 5,459 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Vanda Pharmaceuticals by 16.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 22,249 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Vanda Pharmaceuticals by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 4,449 shares during the period. Barclays PLC raised its holdings in Vanda Pharmaceuticals by 128.2% in the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 86,677 shares during the period. Finally, Geode Capital Management LLC lifted its position in Vanda Pharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock worth $6,689,000 after acquiring an additional 94,870 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.